Dengue (Dengvaxia)
Dengue Vaccine CYD-TDV (Dengvaxia)
Platform: Live recombinant chimeric
Vaccine that protects against dengue fever, a mosquito-borne viral disease caused by four distinct serotypes, recommended only for seropositive individuals.
Immunology Sections
Curated section analysis in progress
Structured immunology sections — mechanism, immune response, molecular signatures, correlates of protection, and more — are being prepared by the Precision Vaccines Program team. In the meantime, verified references and live literature from PubMed, Semantic Scholar, and Wikipedia are available below.
Wikipedia Overview
Full article ↗Dengue vaccine is a vaccine used to prevent dengue fever in humans. Development of dengue vaccines began in the 1920s but was hindered by the need to create immunity against all four dengue serotypes. As of 2023, there are two commercially available vaccines, sold under the brand names Dengvaxia and Qdenga.
PubMed Literature
Search PubMed ↗No PubMed results retrieved.
Semantic Scholar
Search S2 ↗No Semantic Scholar results retrieved.